CA2322549A1 - Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy - Google Patents
Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy Download PDFInfo
- Publication number
- CA2322549A1 CA2322549A1 CA002322549A CA2322549A CA2322549A1 CA 2322549 A1 CA2322549 A1 CA 2322549A1 CA 002322549 A CA002322549 A CA 002322549A CA 2322549 A CA2322549 A CA 2322549A CA 2322549 A1 CA2322549 A1 CA 2322549A1
- Authority
- CA
- Canada
- Prior art keywords
- plant
- cannabis
- powder
- cannabinoid
- profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H3/00—Processes for modifying phenotypes, e.g. symbiosis with bacteria
- A01H3/02—Processes for modifying phenotypes, e.g. symbiosis with bacteria by controlling duration, wavelength, intensity, or periodicity of illumination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H3/00—Processes for modifying phenotypes, e.g. symbiosis with bacteria
- A01H3/04—Processes for modifying phenotypes, e.g. symbiosis with bacteria by treatment with chemicals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/12—Leaves
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/28—Cannabaceae, e.g. cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Abstract
A process is described whereby a back-crossing protocol is used to create cannabis plants which are further standardized into medicinal products. A specific lighting regime is first used to bring a cloned plant to the vegetative stage followed by treatment with defined type of Gibberellic Acid (GA3) which stimulates sex reversal; from a female to a male.
The pollen from this new male is used to pollenate the mother plant with her own pollen.
This procedure creates a new variety of true breeding plant with a reproducible genome, which can be cloned into more plants. Confirmation of reproducibility is achieved us Gas Chromatography/ Mass Spectroscopy (GC/MS) to determine the Cannabinoid Profile of the pollenated plant. This cannabinoid profile is used as an index for the type of medicinal product which can be produced. Once this profile is established the raw material is gound into a powder, the cannabinoid profile is re-verified and the powder can be used as a medicine for symptom relief from many different ailments such as epileptic siezures, glaucoma, nausea/pain, multiple sclerosis tremors, migraine, fibromyalgia, hepatitis, depression, anorexia, anxiety. Route of administration of this powder can be made either oral or by smoking.
The pollen from this new male is used to pollenate the mother plant with her own pollen.
This procedure creates a new variety of true breeding plant with a reproducible genome, which can be cloned into more plants. Confirmation of reproducibility is achieved us Gas Chromatography/ Mass Spectroscopy (GC/MS) to determine the Cannabinoid Profile of the pollenated plant. This cannabinoid profile is used as an index for the type of medicinal product which can be produced. Once this profile is established the raw material is gound into a powder, the cannabinoid profile is re-verified and the powder can be used as a medicine for symptom relief from many different ailments such as epileptic siezures, glaucoma, nausea/pain, multiple sclerosis tremors, migraine, fibromyalgia, hepatitis, depression, anorexia, anxiety. Route of administration of this powder can be made either oral or by smoking.
Description
Cannabis Medicinals Formulation Back-crossing of a given strain of cannabis is used to create a standardized medicinal product as verified by the cannabinoid profile. This medicine can be used for symptom relief from many different conditions.
Background of the Invention The medicinal properties of cannabis have be known for thousands of years.
Chinese medicine men were prescribing it as a treatment for epileptic seizures in 400 BC.
Much more recently a host of scientific data is establishing the role of cannabis as an effective medicine for symptom relief from many different ailments. A method of creating a true breeding strain of cannabis is described which can, in turn, be used to devise a standardized medicinal product. Standardization is based on the cannabinoid profile, a group of compounds which can be identified and quantitated by GC/MS
or by HPLC with a diode array detector. It is these compounds which give cannabis its symptom relieving properties. Knowledge of a given cannabinoid profile allows a practitioner to determine which ailment the medicine can be applied to. In addition, knowledge of the cannabinoid profile allows blending of the powdered cannabis material into a product with distinct cannabinoid ratios to illicit a standardized product.
Objectives of the Invention It is an objective of this invention to produce cannabis clones with defined cannabinoid profiles which can be used as a medicine.
A further objective of this invention is to establish a standard operating procedure of back-crossing to produce a new variety of cannabis plants which can be used as a raw material for producing a medicine.
A further objective of this invention to use cannabinoid profiles determined by Gas Chromatography or by HPLC as an indicator to medicinal properties.
A further objective of this invention is to standardize the product using a back-crossing technique to produce standardized true breeding plants with defined cannabinoid profiles.
A further objective of this invention is to produce a standardized cannabis powder which can be blended with other standardized cannabis powders to make a product containing known amounts of specific cannabinoids.
A further objective of this invention is to establish standard operating procedures whereby reproducible medicinal products can be fabricated from cannabis.
Summary of the Invention According to the present invention a process is described whereby new varieties of cannabis plants can be created which are true breeding. These true breeding plants are standardized to contain known amounts of specific cannabinoid compounds which allow symptom relief from many different ailments. These products are standardized based on their cannabinoid profiles.
Background of the Invention The medicinal properties of cannabis have be known for thousands of years.
Chinese medicine men were prescribing it as a treatment for epileptic seizures in 400 BC.
Much more recently a host of scientific data is establishing the role of cannabis as an effective medicine for symptom relief from many different ailments. A method of creating a true breeding strain of cannabis is described which can, in turn, be used to devise a standardized medicinal product. Standardization is based on the cannabinoid profile, a group of compounds which can be identified and quantitated by GC/MS
or by HPLC with a diode array detector. It is these compounds which give cannabis its symptom relieving properties. Knowledge of a given cannabinoid profile allows a practitioner to determine which ailment the medicine can be applied to. In addition, knowledge of the cannabinoid profile allows blending of the powdered cannabis material into a product with distinct cannabinoid ratios to illicit a standardized product.
Objectives of the Invention It is an objective of this invention to produce cannabis clones with defined cannabinoid profiles which can be used as a medicine.
A further objective of this invention is to establish a standard operating procedure of back-crossing to produce a new variety of cannabis plants which can be used as a raw material for producing a medicine.
A further objective of this invention to use cannabinoid profiles determined by Gas Chromatography or by HPLC as an indicator to medicinal properties.
A further objective of this invention is to standardize the product using a back-crossing technique to produce standardized true breeding plants with defined cannabinoid profiles.
A further objective of this invention is to produce a standardized cannabis powder which can be blended with other standardized cannabis powders to make a product containing known amounts of specific cannabinoids.
A further objective of this invention is to establish standard operating procedures whereby reproducible medicinal products can be fabricated from cannabis.
Summary of the Invention According to the present invention a process is described whereby new varieties of cannabis plants can be created which are true breeding. These true breeding plants are standardized to contain known amounts of specific cannabinoid compounds which allow symptom relief from many different ailments. These products are standardized based on their cannabinoid profiles.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002322549A CA2322549A1 (en) | 2000-09-27 | 2000-09-27 | Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002322549A CA2322549A1 (en) | 2000-09-27 | 2000-09-27 | Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2322549A1 true CA2322549A1 (en) | 2002-03-27 |
Family
ID=4167327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002322549A Abandoned CA2322549A1 (en) | 2000-09-27 | 2000-09-27 | Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2322549A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000830A1 (en) * | 2003-06-24 | 2005-01-06 | Gw Pharma Limited | Pharmaceutical compositions comprising cabbinochreme type compounds |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
-
2000
- 2000-09-27 CA CA002322549A patent/CA2322549A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| WO2005000830A1 (en) * | 2003-06-24 | 2005-01-06 | Gw Pharma Limited | Pharmaceutical compositions comprising cabbinochreme type compounds |
| US8470874B2 (en) | 2003-06-24 | 2013-06-25 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabichromene type compounds |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10207199B2 (en) | Methods of purifying cannabinoids using liquid:liquid chromatography | |
| CA3012514C (en) | Production and use of specialty cannabis with bd/bt genotype and a terpinolene-dominant terpene profile | |
| Valdes et al. | Coleus barbatus (C. forskohlii)(Lamiaceae) and the potential new drug forskolin (Coleonol) | |
| US20160214920A1 (en) | Methods of Purifying Cannabinoids, Compositions and Kits Thereof | |
| Janatová et al. | Yield and cannabinoids contents in different cannabis (Cannabis sativa L.) genotypes for medical use | |
| AU674710B2 (en) | Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics | |
| US10155708B2 (en) | Methods of purifying cannabinoids, compositions and kits thereof | |
| Ruan et al. | Novel 2H-chromen-2-one derivatives of resveratrol: design, synthesis, modeling and use as human monoamine oxidase inhibitors | |
| CA2322549A1 (en) | Medicinal products created from cannabis using cannabinoid profiles as indicators of efficacy | |
| Tucker | Floral development and homeosis in Saraca (Leguminosae: Caesalpinioideae: Detarieae) | |
| CN105054284B (en) | Electronic cigarette atomizing liquid of salubrious elegant odor type and preparation method thereof | |
| JP4044274B2 (en) | Microbial lipase inhibitor, and acne skin external preparation and dandruff skin external preparation containing the same | |
| De Langhe et al. | Effect of hormones on nucleolar growth and vacuolation in elongating cotton fibers | |
| Svajdlenka et al. | Essential oil composition of Thuja occidentalis L. Samples from Slovakia | |
| Mariswamy et al. | GC-MS studies on methanolic extracts of Aerva lanata L | |
| Kaffash et al. | Comparing essential oil composition of cultivated and wild samples of Achillea biebersteinii Afan. in Kurdistan Province. | |
| Scott | Medicinal and aromatic plants | |
| BOKOV | MUSCARI ARMENIACUM LEICHTLIN (GRAPE HYACINTH): PHYTOCHEMISTRY AND BIOLOGICAL ACTIVITIES REVIEW | |
| Carvalho et al. | Pharmaceutical Evaluation of Medical Cannabis Extracts Prepared by Artisanal and Laboratory Techniques | |
| Cox | Assessment of Cannabinoid levels in Successively Cloned Generations of industrial hemp (Cannabis sarivas) | |
| Debbab et al. | Chemical characterization and toxicological evaluation of the essential oil of Mentha piperita L. growing in Morocco | |
| CN108440478A (en) | A kind of formulation preparation method with purifying natural dihydromyricetin | |
| Chandra et al. | Effect of vermicompost on useable biomass yield, cannabinoids and terpenes content of indoor grown Cannabis sativa L. plants. | |
| US20220386548A1 (en) | Cannabis plant named 'hba-2-x' | |
| Chagonda et al. | Essential oils of cultivated Heteropyxis natalensis (Harv.) and cultivated Heteromorpha trifoliata (Wendl.) Eckl. & Zey. from Zimbabwe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |